医療用デフェロキサミンメシル酸塩の世界市場レポート 2025年

医療用デフェロキサミンメシル酸塩市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.7％で18億米ドルに成長します。予測期間中の成長が期待される背景には、サラセミアや鎌状赤血球症の有病率の上昇、鉄キレート療法の需要拡大、医療への幅広いアクセス、鉄過剰症合併症に対する意識の高まり、希少疾患に対する政府の支援策、製薬企業による研究開発への投資拡大などの要因があります。予測期間における主な動向としては、新しいドラッグデリバリーシステムの進歩、遺伝子治療との統合、長時間作用型製剤の開発、キレート療法の進歩などが挙げられます。

鉄過剰症の有病率の増加は、今後数年間の医療用デフェロキサミンメシル酸塩市場の拡大を牽引すると予想されます。体内の鉄の過剰蓄積を特徴とするこれらの障害は、遺伝的要因、頻繁な輸血、特定の慢性疾患によって生じる可能性があります。慢性ヘモグロビン異常症を管理するための長期輸血の増加は、患者の生存率の向上と並んで、リスクを抱える人口の増加に寄与しており、それによって鉄過剰症の発生率が増加しています。医療用デフェロキサミンメシル酸塩は、過剰な鉄を除去し、臓器障害を予防し、サラセミアやヘモクロマトーシスなどの患者を支援することで、これらの疾患の治療に重要な役割を果たしています。例えば、Electronic Journal of General Medicine誌の2023年3月の報告によると、患者の10.73％（1,085人）がα-サラセミア、2.24％（227人）がβ-サラセミア、0.29％（29人）が両方の変異を有していました。このように、鉄過剰症の有病率の上昇が医療用デフェロキサミンメシル酸塩市場の成長を牽引しています。

医療用デフェロキサミンメシル酸塩市場の主なプレーヤーは、患者アクセスの改善、治療コストの削減、世界市場での競争力強化のため、ジェネリック医薬品の開発に注力しています。ジェネリック医薬品は、先発医薬品の代替品としてより手頃な価格で提供されるものであり、先発医薬品の特許が切れた後も同じ有効成分を含み、同じ治療効果をもたらします。例えば、カナダの製薬会社ファーマサイエンス社は2023年1月、ジャデヌの費用対効果の高い代替薬PRpms-DEFERASIROX（TYPE J）を発売しました。この薬は、小児および成人の貧血またはサラセミア患者における慢性鉄過剰症の治療に使用され、90mgと360mgの錠剤で同じ安全性と有効性を提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場 - 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の医療用デフェロキサミンメシル酸塩PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の医療用デフェロキサミンメシル酸塩市場：成長率分析
• 世界の医療用デフェロキサミンメシル酸塩市場の実績：規模と成長, 2019-2024
• 世界の医療用デフェロキサミンメシル酸塩市場の予測：規模と成長, 2024-2029, 2034F
• 世界の医療用デフェロキサミンメシル酸塩総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の医療用デフェロキサミンメシル酸塩市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射
• 経口
• 局所
• 世界の医療用デフェロキサミンメシル酸塩市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 皮下
• 筋肉内
• 静脈内
• 世界の医療用デフェロキサミンメシル酸塩市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他
• 世界の医療用デフェロキサミンメシル酸塩市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 鉄過剰症
• アルミニウム中毒
• 急性鉄中毒
• その他
• 世界の医療用デフェロキサミンメシル酸塩市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 世界の医療用デフェロキサミンメシル酸塩市場、注射の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 筋肉内（IM）
• 静脈内（IV）
• 皮下（SC）
• 世界の医療用デフェロキサミンメシル酸塩市場、経口の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• タブレット
• カプセル
• 液体懸濁液
• 世界の医療用デフェロキサミンメシル酸塩市場、局所の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ゲル
• クリーム
• 軟膏

第7章 地域別・国別分析

• 世界の医療用デフェロキサミンメシル酸塩市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の医療用デフェロキサミンメシル酸塩市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 医療用デフェロキサミンメシル酸塩市場：競合情勢
• 医療用デフェロキサミンメシル酸塩市場：企業プロファイル
  • McKesson Corporation Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Inc.（TAPI）Overview, Products and Services, Strategy and Financial Analysis
  • Intas Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Fresenius Kabi AG
• Apotex Inc.
• Fareva SA
• Lupin Limited
• Glenmark Pharmaceuticals Ltd.
• Torrent Pharmaceuticals Ltd.
• Wockhardt Ltd.
• Hospira Inc.
• Cayman Chemical Company, Inc.
• Selleck Chemicals LLC
• Tocris Bioscience
• Bills Biotech
• JIGS CHEMICAL LIMITED.
• Manus Aktteva Biopharma LLP
• Merit Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 医療用デフェロキサミンメシル酸塩市場2029：新たな機会を提供する国
• 医療用デフェロキサミンメシル酸塩市場2029：新たな機会を提供するセグメント
• 医療用デフェロキサミンメシル酸塩市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Medical deferoxamine mesylate is a medication used to remove excess iron from the body. It is primarily prescribed to individuals with dangerously high iron levels, often due to frequent blood transfusions. The drug binds to the excess iron, enabling the body to safely eliminate it through urine or bile.

The main types of medical deferoxamine mesylate products include injectable, oral, and topical formulations. Injectable products are delivered into the body using a needle and syringe, with administration methods including subcutaneous, intramuscular, and intravenous routes. These products are distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. Key applications of deferoxamine mesylate include the treatment of iron overload disorders, aluminum toxicity, and acute iron poisoning. It is primarily used by hospitals and clinics among other healthcare providers.

The medical deferoxamine mesylate market research report is one of a series of new reports from The Business Research Company that provides medical deferoxamine mesylate market statistics, including the medical deferoxamine mesylate industry global market size, regional shares, competitors with the medical deferoxamine mesylate market share, detailed medical deferoxamine mesylate market segments, market trends, and opportunities, and any further data you may need to thrive in the medical deferoxamine mesylate industry. This medical deferoxamine mesylate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The medical deferoxamine mesylate market size has grown strongly in recent years. It will grow from $1.18 billion in 2024 to $1.29 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth observed in the historical period can be linked to the increasing prevalence of iron overload disorders, a rise in cases of thalassemia and sickle cell anemia, higher global blood transfusion rates, expansion of healthcare infrastructure, greater government funding for rare disease treatments, and improved diagnosis rates for chronic iron-related conditions.

The medical deferoxamine mesylate market size is expected to see strong growth in the next few years. It will grow to $1.80 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The expected growth in the forecast period is driven by factors such as the rising prevalence of thalassemia and sickle cell disease, growing demand for iron chelation therapies, broader access to healthcare, increasing awareness of iron overload complications, supportive government initiatives for rare diseases, and more investments in research and development by pharmaceutical companies. Key trends in the forecast period include advancements in new drug delivery systems, integration with gene therapy treatments, the development of long-acting formulations, and progress in chelation therapy.

The growing prevalence of iron overload disorders is anticipated to drive the expansion of the medical deferoxamine mesylate market in the coming years. These disorders, characterized by an excessive accumulation of iron in the body, can result from genetic factors, frequent blood transfusions, or certain chronic illnesses. The increased use of long-term blood transfusions for managing chronic hemoglobinopathies, alongside improved patient survival rates, has contributed to a larger population at risk, thereby increasing the incidence of iron overload disorders. Medical deferoxamine mesylate plays a crucial role in treating these conditions by removing excess iron, preventing organ damage, and assisting patients with conditions such as thalassemia and hemochromatosis. For example, a March 2023 report from the Electronic Journal of General Medicine noted that 10.73% of patients (1,085) had alpha-thalassemia, 2.24% (227) had beta-thalassemia, and 0.29% (29) had both mutations. Thus, the rising prevalence of iron overload disorders is driving the growth of the medical deferoxamine mesylate market.

Key players in the medical deferoxamine mesylate market are focusing on developing generic versions of drugs to improve patient access, lower treatment costs, and enhance their competitive standing in the global market. Generic drugs, which are more affordable alternatives to branded medicines, contain the same active ingredients and provide the same therapeutic benefits once the original patent expires. For example, in January 2023, Pharmascience Inc., a Canadian pharmaceutical company, introduced PRpms-DEFERASIROX (TYPE J), a cost-effective substitute for Jadenu. This medication, used to treat chronic iron overload in both children and adults with anemia or thalassemia, offers the same safety and efficacy in 90 mg and 360 mg tablet forms.

In September 2024, Mitem Pharma, a French pharmaceutical company, acquired the global rights to DESFERAL (deferoxamine mesylate) from Novartis AG for an undisclosed amount. This acquisition strengthens Mitem Pharma's position in the iron chelation therapy market and enhances its portfolio with a well-established treatment for managing iron overload disorders. Novartis AG, a Swiss-based pharmaceutical company, is known for producing therapeutic drugs for rare diseases.

Major players in the medical deferoxamine mesylate market are McKesson Corporation, Novartis AG, Merck KGaA, Teva Pharmaceutical Industries Inc. (TAPI), Intas Pharmaceuticals Ltd., Fresenius Kabi AG, Apotex Inc., Fareva SA, Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Ltd., Hospira Inc., Cayman Chemical Company, Inc., Selleck Chemicals LLC, Tocris Bioscience, Bills Biotech, JIGS CHEMICAL LIMITED., Manus Aktteva Biopharma LLP, Merit Pharmaceuticals Inc.

North America was the largest region in the medical deferoxamine mesylate market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in medical deferoxamine mesylate report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the medical deferoxamine mesylate market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The medical deferoxamine mesylate market consists of sales of infusion pumps, syringes, and generic version of drug. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Medical Deferoxamine Mesylate Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on medical deferoxamine mesylate market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for medical deferoxamine mesylate ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The medical deferoxamine mesylate market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Injectable; Oral; Topical
• 2) By Route Of Administration: Subcutaneous; Intramuscular; Intravenous
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Others Distribution Channel
• 4) By Application: Iron Overload Disorders; Aluminum Toxicity; Acute Iron Poisoning; Other Applications
• 5) By End-User: Hospitals; Clinics

Subsegments

• 1) By Injectable: Intramuscular (IM); Intravenous (IV); Subcutaneous (SC)
• 2) By Oral: Tablets; Capsules; Liquid Suspensions
• 3) By Topical: Gels; Creams; Ointments
• Companies Mentioned: McKesson Corporation; Novartis AG; Merck KGaA; Teva Pharmaceutical Industries Inc. (TAPI); Intas Pharmaceuticals Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Medical Deferoxamine Mesylate Market Characteristics

3. Medical Deferoxamine Mesylate Market Trends And Strategies

4. Medical Deferoxamine Mesylate Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Medical Deferoxamine Mesylate Growth Analysis And Strategic Analysis Framework

• 5.1. Global Medical Deferoxamine Mesylate PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Medical Deferoxamine Mesylate Market Growth Rate Analysis
• 5.4. Global Medical Deferoxamine Mesylate Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Medical Deferoxamine Mesylate Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Medical Deferoxamine Mesylate Total Addressable Market (TAM)

6. Medical Deferoxamine Mesylate Market Segmentation

• 6.1. Global Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable
• Oral
• Topical
• 6.2. Global Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subcutaneous
• Intramuscular
• Intravenous
• 6.3. Global Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others Distribution Channel
• 6.4. Global Medical Deferoxamine Mesylate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Iron Overload Disorders
• Aluminum Toxicity
• Acute Iron Poisoning
• Other Applications
• 6.5. Global Medical Deferoxamine Mesylate Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• 6.6. Global Medical Deferoxamine Mesylate Market, Sub-Segmentation Of Injectable, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intramuscular (IM)
• Intravenous (IV)
• Subcutaneous (SC)
• 6.7. Global Medical Deferoxamine Mesylate Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Capsules
• Liquid Suspensions
• 6.8. Global Medical Deferoxamine Mesylate Market, Sub-Segmentation Of Topical, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gels
• Creams
• Ointments

7. Medical Deferoxamine Mesylate Market Regional And Country Analysis

• 7.1. Global Medical Deferoxamine Mesylate Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Medical Deferoxamine Mesylate Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Medical Deferoxamine Mesylate Market

• 8.1. Asia-Pacific Medical Deferoxamine Mesylate Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Medical Deferoxamine Mesylate Market

• 9.1. China Medical Deferoxamine Mesylate Market Overview
• 9.2. China Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Medical Deferoxamine Mesylate Market

• 10.1. India Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Medical Deferoxamine Mesylate Market

• 11.1. Japan Medical Deferoxamine Mesylate Market Overview
• 11.2. Japan Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Medical Deferoxamine Mesylate Market

• 12.1. Australia Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Medical Deferoxamine Mesylate Market

• 13.1. Indonesia Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Medical Deferoxamine Mesylate Market

• 14.1. South Korea Medical Deferoxamine Mesylate Market Overview
• 14.2. South Korea Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Medical Deferoxamine Mesylate Market

• 15.1. Western Europe Medical Deferoxamine Mesylate Market Overview
• 15.2. Western Europe Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Medical Deferoxamine Mesylate Market

• 16.1. UK Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Medical Deferoxamine Mesylate Market

• 17.1. Germany Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Medical Deferoxamine Mesylate Market

• 18.1. France Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Medical Deferoxamine Mesylate Market

• 19.1. Italy Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Medical Deferoxamine Mesylate Market

• 20.1. Spain Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Medical Deferoxamine Mesylate Market

• 21.1. Eastern Europe Medical Deferoxamine Mesylate Market Overview
• 21.2. Eastern Europe Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Medical Deferoxamine Mesylate Market

• 22.1. Russia Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Medical Deferoxamine Mesylate Market

• 23.1. North America Medical Deferoxamine Mesylate Market Overview
• 23.2. North America Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Medical Deferoxamine Mesylate Market

• 24.1. USA Medical Deferoxamine Mesylate Market Overview
• 24.2. USA Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Medical Deferoxamine Mesylate Market

• 25.1. Canada Medical Deferoxamine Mesylate Market Overview
• 25.2. Canada Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Medical Deferoxamine Mesylate Market

• 26.1. South America Medical Deferoxamine Mesylate Market Overview
• 26.2. South America Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Medical Deferoxamine Mesylate Market

• 27.1. Brazil Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Medical Deferoxamine Mesylate Market

• 28.1. Middle East Medical Deferoxamine Mesylate Market Overview
• 28.2. Middle East Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Medical Deferoxamine Mesylate Market

• 29.1. Africa Medical Deferoxamine Mesylate Market Overview
• 29.2. Africa Medical Deferoxamine Mesylate Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Medical Deferoxamine Mesylate Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Medical Deferoxamine Mesylate Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Medical Deferoxamine Mesylate Market Competitive Landscape And Company Profiles

• 30.1. Medical Deferoxamine Mesylate Market Competitive Landscape
• 30.2. Medical Deferoxamine Mesylate Market Company Profiles
  • 30.2.1. McKesson Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Teva Pharmaceutical Industries Inc. (TAPI) Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Intas Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Medical Deferoxamine Mesylate Market Other Major And Innovative Companies

• 31.1. Fresenius Kabi AG
• 31.2. Apotex Inc.
• 31.3. Fareva SA
• 31.4. Lupin Limited
• 31.5. Glenmark Pharmaceuticals Ltd.
• 31.6. Torrent Pharmaceuticals Ltd.
• 31.7. Wockhardt Ltd.
• 31.8. Hospira Inc.
• 31.9. Cayman Chemical Company, Inc.
• 31.10. Selleck Chemicals LLC
• 31.11. Tocris Bioscience
• 31.12. Bills Biotech
• 31.13. JIGS CHEMICAL LIMITED.
• 31.14. Manus Aktteva Biopharma LLP
• 31.15. Merit Pharmaceuticals Inc.

32. Global Medical Deferoxamine Mesylate Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Medical Deferoxamine Mesylate Market

34. Recent Developments In The Medical Deferoxamine Mesylate Market

35. Medical Deferoxamine Mesylate Market High Potential Countries, Segments and Strategies

• 35.1 Medical Deferoxamine Mesylate Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Medical Deferoxamine Mesylate Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Medical Deferoxamine Mesylate Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer